NovalGen is a clinical stage company developing breakthrough multi-specific immunotherapies that generate transformative outcomes in autoimmune, oncological, and other immunological disorders.
NovalGen is focused on the development of cutting-edge new therapeutics, utilizing its proprietary autoregulation platform technology to deliver safer treatment strategies with improved outcomes for our patients.
Our history
Headquartered in London, UK, NovalGen was formed in 2019. The company is based on proprietary innovation from UCL, London UK.
Our values
NovalGen is guided by our core set of values. The culture of NovalGen reflects these values and they help guide our decisions.
